Journal for ImmunoTherapy of Cancer: 10 (5)

Current Issue

May 2022 - Volume 10 - 5

Basic tumor immunology

Original research: Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity (19 May, 2022)
Pierre-Louis Bernard, Rebecca Delconte, Sonia Pastor, Vladimir Laletin, Cathy Costa Da Silva, Armelle Goubard, Emmanuelle Josselin, Rémy Castellano, Adrien Krug, Julien Vernerey, Raynier Devillier, Daniel Olive, Els Verhoeyen, Eric Vivier, Nicholas D Huntington, Jacques Nunes, Geoffrey Guittard
Original research: Mitoribosomal defects aggravate liver cancer via aberrant glycolytic flux and T cell exhaustion (17 May, 2022)
Byong-Sop Song, Ji Sun Moon, Jingwen Tian, Ho Yeop Lee, Byeong Chang Sim, Seok-Hwan Kim, Seul Gi Kang, Jung Tae Kim, Ha Thi Nga, Rui Benfeitas, Yeongmin Kim, Sanghee Park, Robert R. Wolfe, Hyuk Soo Eun, Minho Shong, Sunjae Lee, Il-Young Kim, Hyon-Seung Yi
Original research: Targeting SNORA38B attenuates tumorigenesis and sensitizes immune checkpoint blockade in non-small cell lung cancer by remodeling the tumor microenvironment via regulation of GAB2/AKT/mTOR signaling pathway (16 May, 2022)
Yue Zhuo, Shujun Li, Wei Hu, Yu Zhang, Yufan Shi, Faxue Zhang, Jian Zhang, Juan Wang, Meijuan Liao, Jiahao Chen, Huiling Qian, Dejia Li, Chengcao Sun
Original research: Albendazole induces immunotherapy response by facilitating ubiquitin-mediated PD-L1 degradation (16 May, 2022)
Lin Zhu, Xinwei Kuang, Guanxiong Zhang, Long Liang, Dandan Liu, Bin Hu, Zuozhong Xie, Hui Li, Hong Liu, Mao Ye, Xiang Chen, Jing Liu
Original research: Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment (12 May, 2022)
Angela Pizzolla, Simon Paul Keam, Ismael A Vergara, Franco Caramia, Niko Thio, Minyu Wang, Nikolce Kocovski, Daniela Tantalo, Jafar Jabbari, George Au-Yeung, Shahneen Sandhu, David E Gyorki, Alison Weppler, Maurizio Perdicchio, Grant A McArthur, Anthony T Papenfuss, Paul Joseph Neeson

Clinical/translational cancer immunotherapy

Original research: Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin’s lymphoma: a phase II, non-randomized controlled trial (18 May, 2022)
Jessica Hochberg, Jaclyn Basso, Qiuhu Shi, Liana Klejmont, Allyson Flower, Kristina Bortfeld, Lauren Harrison, Carmella van de Ven, Chitti Moorthy, Humayun Islam, Perry Gerard, Stephan Voss, Mitchell S Cairo
Original research:
A_2B adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models
(17 May, 2022)
Apple Hui Min Tay, Rubén Prieto-Díaz, Shiyong Neo, Le Tong, Xinsong Chen, Valentina Carannante, Björn Önfelt, Johan Hartman, Felix Haglund, Maria Majellaro, Jhonny Azuaje, Xerardo Garcia-Mera, Jose M Brea, Maria I Loza, Willem Jespers, Hugo Gutierrez-de-Teran, Eddy Sotelo, Andreas Lundqvist
Original research: Activin-A impairs CD8 T cell-mediated immunity and immune checkpoint therapy response in melanoma (17 May, 2022)
Katarina Pinjusic, Olivier Andreas Dubey, Olga Egorova, Sina Nassiri, Etienne Meylan, Julien Faget, Daniel Beat Constam
Original research:
CD4⁺ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
(17 May, 2022)
Minglu Xiao, Luoyingzi Xie, Guoshuai Cao, Shun Lei, Pengcheng Wang, Zhengping Wei, Yuan Luo, Jingyi Fang, Xingxing Yang, Qizhao Huang, Lifan Xu, Junyi Guo, Shuqiong Wen, Zhiming Wang, Qing Wu, Jianfang Tang, Lisha Wang, Xiangyu Chen, Cheng Chen, Yanyan Zhang, Wei Yao, Jianqiang Ye, Ran He, Jun Huang, Lilin Ye
Original research: Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial (17 May, 2022)
Federica Riccardo, Lidia Tarone, Mariateresa Camerino, Davide Giacobino, Selina Iussich, Giuseppina Barutello, Maddalena Arigoni, Laura Conti, Elisabetta Bolli, Elena Quaglino, Irene Fiore Merighi, Emanuela Morello, Alfredo Dentini, Soldano Ferrone, Paolo Buracco, Federica Cavallo
Original research: Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade (16 May, 2022)
Carlos Gomez-Roca, Philippe Cassier, Dmitriy Zamarin, Jean-Pascal Machiels, Jose Luis Perez Gracia, F Stephen Hodi, Alvaro Taus, Maria Martinez Garcia, Valentina Boni, Joseph P Eder, Navid Hafez, Ryan Sullivan, David Mcdermott, Stephane Champiat, Sandrine Aspeslagh, Catherine Terret, Anna-Maria Jegg, Wolfgang Jacob, Michael A Cannarile, Carola Ries, Konstanty Korski, Francesca Michielin, Randolph Christen, Galina Babitzki, Carl Watson, Georgina Meneses-Lorente, Martin Weisser, Dominik Rüttinger, Jean-Pierre Delord, Aurelien Marabelle
Original research: Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma (11 May, 2022)
Gino Kim In, Aparna Nallagangula, Jacob Seung Choi, Lisa Tachiki, Matthew J Blackburn, Stephen Capone, Kathryn B Bollin, Daniel Y. Reuben, Keisuke Shirai, Sandy Zhang-Nunes, Omar Ragab, Alicia Terando, Jenny C. Hu, Han Lee, Shailender Bhatia, Sunandana Chandra, Jose Lutzky, Geoffrey Thomas Gibney
Original research: Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study (10 May, 2022)
Yuan-Yuan Qu, Zhongquan Sun, Weiqing Han, Qing Zou, Nianzeng Xing, Hong Luo, Xuepei Zhang, Chaohong He, Xiao-Jie Bian, Jinling Cai, Chunxia Chen, Quanren Wang, Ding-Wei Ye
Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation (9 May, 2022)
Elizabeth M Holland, John C Molina, Kniya Dede, Daniel Moyer, Ting Zhou, Constance M Yuan, Hao-Wei Wang, Maryalice Stetler-Stevenson, Crystal Mackall, Terry J Fry, Sandhya Panch, Steven Highfill, David Stroncek, Lauren Little, Daniel W Lee, Haneen Shalabi, Bonnie Yates, Nirali Shah

Immunotherapy biomarkers

Original research: Deconvolution of malignant pleural effusions immune landscape unravels a novel macrophage signature associated with worse clinical outcome in lung adenocarcinoma patients (18 May, 2022)
Sara Bruschini, Matteo Pallocca, Eleonora Sperandio, Lorenzo D’Ambrosio, Francesca Ascenzi, Claudia De Vitis, Valentina Salvati, Antonella Esposito, Simona Di Martino, Francesca De Nicola, Francesca Paolini, Luigi Fattore, Gabriele Alessandrini, Francesco Facciolo, Maria Laura Foddai, Massimiliano Bassi, Federico Venuta, Michela D’Ascanio, Alberto Ricci, Antonio D’ Andrilli, Christian Napoli, Luigi Aurisicchio, Maurizio Fanciulli, Erino Angelo Rendina, Gennaro Ciliberto, Rita Mancini
Original research: Soluble HLA peptidome of pleural effusions is a valuable source for tumor antigens (17 May, 2022)
Sofia Khazan-Kost, Gal Cafri, Dganit Melamed Kadosh, Navit Mooshayef, Sumit Chatterji, Dan Dominissini, Sigal Manor, Bracha Zisser, Limor Broday, Efrosiniia Talalai, Anat Shemer, Oranit Zadok, Efrat Ofek, Amir Onn, Arie Admon, Michael Peled
Original research:
Intrahepatic inflammatory IgA⁺PD-L1^high monocytes in hepatocellular carcinoma development and immunotherapy
(16 May, 2022)
Pil Soo Sung, Dong Jun Park, Pu Reun Roh, Kyoung Do Mun, Sung Woo Cho, Gil Won Lee, Eun Sun Jung, Sung Hak Lee, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Jonghwan Choi, Jaegyoon Ahn, Seung Kew Yoon
Original research: Clinical significance of plasma-free amino acids and tryptophan metabolites in patients with non-small cell lung cancer receiving PD-1 inhibitor: a pilot cohort study for developing a prognostic multivariate model (15 May, 2022)
Koichi Azuma, Huihui Xiang, Tomoyuki Tagami, Rika Kasajima, Yumiko Kato, Sachise Karakawa, Shinya Kikuchi, Akira Imaizumi, Norikazu Matsuo, Hidenobu Ishii, Takaaki Tokito, Akihiko Kawahara, Kenta Murotani, Tetsuro Sasada, Yohei Miyagi, Tomoaki Hoshino
Original research: Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome (12 May, 2022)
Mark A J Gorris, Lieke L van der Woude, Leonie I Kroeze, Kalijn Bol, Kiek Verrijp, Avital L Amir, Jelena Meek, Johannes Textor, Carl G Figdor, I Jolanda M de Vries
Original research: NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer (5 May, 2022)
Sen Yan, Han Zeng, Kaifeng Jin, Fei Shao, Zhaopei Liu, Yuan Chang, Yiwei Wang, Yu Zhu, Zewei Wang, Le Xu, Jiejie Xu

Immune cell therapies and immune cell engineering

Original research: The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL (17 May, 2022)
Kai Rejeski, Ariel Perez, Gloria Iacoboni, Olaf Penack, Veit Bücklein, Liv Jentzsch, Dimitrios Mougiakakos, Grace Johnson, Brian Arciola, Cecilia Carpio, Viktoria Blumenberg, Eva Hoster, Lars Bullinger, Frederick L Locke, Michael von Bergwelt-Baildon, Andreas Mackensen, Wolfgang Bethge, Pere Barba, Michael D Jain, Marion Subklewe

Oncolytic and local immunotherapy

Original research: TNF blockade enhances the efficacy of myxoma virus-based oncolytic virotherapy (16 May, 2022)
Miriam Valenzuela-Cardenas, Cody Gowan, Parker Dryja, Mee Y Bartee, Eric Bartee

Review

Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells (17 May, 2022)
Sainiteesh Maddineni, John L Silberstein, John B Sunwoo
Time to evolve: predicting engineered T cell-associated toxicity with next-generation models (16 May, 2022)
Emmanuel Donnadieu, Maik Luu, Miriam Alb, Brigitte Anliker, Silvia Arcangeli, Chiara Bonini, Biagio De Angelis, Rashmi Choudhary, David Espie, Anne Galy, Cam Holland, Zoltán Ivics, Chahrazade Kantari-Mimoun, Marie Jose Kersten, Ulrike Köhl, Chantal Kuhn, Bruno Laugel, Franco Locatelli, Ibtissam Marchiq, Janet Markman, Marta Angiola Moresco, Emma Morris, Helene Negre, Concetta Quintarelli, Michael Rade, Kristin Reiche, Matthias Renner, Eliana Ruggiero, Carmen Sanges, Hans Stauss, Maria Themeli, Jan Van den Brulle, Michael Hudecek, Monica Casucci
Time 2EVOLVE: predicting efficacy of engineered T-cells – how far is the bench from the bedside? (16 May, 2022)
Sonia Guedan, Maik Luu, Delphine Ammar, Paula Barbao, Chiara Bonini, Philippe Bousso, Christian J Buchholz, Monica Casucci, Biagio De Angelis, Emmanuel Donnadieu, David Espie, Beatrice Greco, Richard Groen, Johannes B Huppa, Chahrazade Kantari-Mimoun, Bruno Laugel, Mary Mantock, Janet L Markman, Emma Morris, Concetta Quintarelli, Michael Rade, Kristin Reiche, Alba Rodriguez-Garcia, Juan Roberto Rodriguez-Madoz, Eliana Ruggiero, Maria Themeli, Michael Hudecek, Ibtissam Marchiq

Log in using your username and password

Main menu

Log in using your username and password

You are here

Current Issue

May 2022 - Volume 10 - 5

Basic tumor immunology

Clinical/translational cancer immunotherapy

Immunotherapy biomarkers

Immune cell therapies and immune cell engineering

Oncolytic and local immunotherapy

Review